Ultime notizie per Aprea Therapeutics (NASDAQ:APRE) Azioni

Aprea Therapeutics

Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.

Aprea Therapeutics Inc

Aprea Therapeutics GAAP EPS of -$0.58, revenue of $561.57M

In a report released today, Robert Driscoll from Wedbush initiated coverage with a Buy rating on Aprea Therapeutics (APRE – Research Report) and a ...

Wedbush Initiates a Buy Rating on Aprea Therapeutics (APRE)

Maxim Group analyst Jason McCarthy reiterated a Buy rating on Aprea Therapeutics (APRE – Research Report) yesterday and set a price target of $16.0...

Buy Rating Justified by Aprea Therapeutics' Financial Health and Innovative Clinical Trials

Aprea Therapeutics (APRE) announced that preliminary safety results on its WEE1 inhibitor APR-1051 are highlighted in a poster being presented toda...

Aprea Therapeutics presents preliminary results on APR-1051

Aprea Therapeutics ( ($APRE) ) just unveiled an announcement. Aprea Therapeutics has announced promising preliminary safety results for its WEE1 in...

Aprea Therapeutics Reports Promising Results for APR-1051 Trials

Aprea Therapeutics falls on data from APR-1051 study in cancer-associated gene alterations

In a report released yesterday, Jason McCarthy from Maxim Group reiterated a Buy rating on Aprea Therapeutics (APRE – Research Report), with a pric...

Promising Safety and Financial Strength Propel Buy Rating for Aprea Therapeutics

Aprea Therapeutics GAAP EPS of -$0.64

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Aprea Therapeutics (APRE – Research Report), with a pric...

Buy Recommendation for Aprea Therapeutics Based on Promising Clinical Progress and Strategic Financial Positioning

H.C. Wainwright analyst Joseph Pantginis has reiterated their bullish stance on APRE stock, giving a Buy rating on November 7. Joseph Pantginis has...

Aprea Therapeutics: Buy Rating Driven by Clinical Progress and Financial Stability

APRE

News

Press Releases

Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference

Health Care

UPDATE - Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference

Aprea Therapeutics to Present at the Life Sciences Investor Forum on September 19

Aprea Therapeutics to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024

Halda Therapeutics Appoints Veteran Biopharma Leader, Christian Schade, as President and Chief Executive Officer

Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development

Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics

Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit

Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics

Earnings

Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

IART

OMGA

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

AIM ImmunoTech

BioCardia

bioAffinity Technologies, Inc. - Common Stock

bioAffinity Technologies

BioXcel Therapeutics, Inc. - Common Stock

BioXcel Therapeutics

Cardio Diagnostics Holdings Inc. - Common stock

Cardio Diagnostics Hldgs

Cyclo Therapeutics

Ensysce Biosciences

GlycoMimetics

Imunon

Immuron Limited - American Depositary Shares

Immuron

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics

MEI Pharma

Mainz Biomed

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences

NKGen Biotech

Nanoviricides

NeuroBo Pharmaceuticals, Inc. - Common Stock

NeuroBo Pharmaceuticals

PharmaCyte Biotech

Palatin Techs

Sensei Biotherapeutics, Inc. - Common Stock

Comments

Aprea Therapeutics

Notizie

Ultime notizie per Aprea Therapeutics (NASDAQ:APRE) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO